FDA taps data-mining tech for drug safety research

As the FDA takes new measures to identify drug safety issues, the agency has licensed text-mining software from Cambridge, U.K.-based Linguamatics for lab research of drug toxicity. The deal gives the U.S. regulator access to the company's I2E technology, which its labs plan to use to mine text from publications and drug labels. Article

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.